Conditions: Alzheimer Disease
Keywords: open-label safety antibody
Allocation: NON_RANDOMIZED | Intervention model: PARALLEL
Enrollment: 62
Healthy volunteers: no

Brief summary:
This study will evaluate the safety and tolerability of bapineuzumab when administered by subcutaneous injection. The study is open only to subjects who participated in the preceding double-blind study (3133L1-2203 US). Subjects will receive weekly injections of bapineuzumab for 3 years (156 doses). One dosage level will be included: 5 mg/week. All subjects will receive active treatment (bapineuzumab) and no subjects will receive placebo.

Detailed description:

Arms:
arm 1: 5 mg/week

Interventions: intervention 1: bapineuzumab
Intervention descriptions: intervention 1: 5 mg/week subcutaneous bapineuzumab

Protocol document: